Home›Lutetium Lu 177 Dotatate›Lutetium Lu 177 Dotatate + Octreotide Acetate

Does Lutetium Lu 177 Dotatate Interact with Octreotide Acetate?

CDI records a contraindicated classification for Lutetium Lu 177 Dotatate and Octreotide Acetate. The stored summary is: Octreotide competitively binds somatostatin receptors and may interfere with lutetium Lu 177 dotatate efficacy. Discontinue octreotide at least 24 hours prior to each lutetium dose. The mechanism involves competitive binding to somatostatin receptors. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity: Contraindicated
Management: Do not take together
Data Source: U.S. FDA via OpenFDA

Recorded Mechanism

Competitive binding to somatostatin receptors

What To Tell Your Doctor or Pharmacist

If you are taking Lutetium Lu 177 Dotatate and your doctor is considering prescribing Octreotide Acetate (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask about alternative medications that do not interact with your current regimen
Ask how frequently you should be monitored while these are co-prescribed
Never stop or change either medication without first consulting your healthcare provider

💊 Lutetium Lu 177 Dotatate(Lutathera)+💊 Octreotide Acetate(Octreotide Acetate)

Severity & Interaction Details

⛔

contraindicated

Avoid this combination

CDI classifies this record as contraindicated. Confirm the applicable product labeling with your prescriber or pharmacist.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

—

Source

NLP:octreotide acetate

What this means in plain English

Octreotide competitively binds somatostatin receptors and may interfere with lutetium Lu 177 dotatate efficacy. Discontinue octreotide at least 24 hours prior to each lutetium dose.

About Lutetium Lu 177 Dotatate and Octreotide Acetate

Lutetium Lu 177 Dotatate is also sold under the brand name Lutathera.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:octreotide acetate

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Lutetium Lu 177 Dotatate and Octreotide Acetate against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.